NFL Biosciences

Executive Summary

NFL Biosciences is a French biopharmaceutical company founded in 2015, specializing in botanical medicines for addiction treatment. Its lead candidates, NFL-101 and NFL-102, are derived from a nicotine-free tobacco leaf protein extract and are being developed for smoking cessation. The company is currently in the pre-clinical stage, with all R&D activities outsourced to minimize costs and accelerate development. NFL Biosciences aims to partner its programs with larger pharmaceutical companies for late-stage clinical development and commercialization, leveraging its unique natural product platform. The novel approach could offer a differentiated option in the smoking cessation market, but the early-stage nature of the pipeline carries significant technical and regulatory risks. Success hinges on advancing candidates through preclinical studies and securing strategic partnerships to fund and execute clinical trials.

Upcoming Catalysts (preview)

• TBDInitiation of Phase 1 clinical trial for NFL-10140% success
• TBDPartnership or licensing agreement for NFL-10230% success
• TBDCompletion of preclinical toxicology studies50% success